{"preliminary_commentary":{"by_channel":{"podcast":55,"youtube":53,"x_thread":42},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. A report screens them, searches for more and cites what clinicians said when it is built, so final coverage is set at build."},"free_build":{"available":true,"how":"POST https://www.erudio.com/api/trial-requests with {\"nct_id\": \"NCT04484142\", \"email\": \"<work email>\"}. The person who owns that inbox must confirm by the emailed link; agents cannot confirm. The result is the report's free public preview; the full report is still bought."},"name":"TROPION-Lung05","nct_id":"NCT04484142","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=tropion-lung05-nct04484142. The price is an estimate of verified HCP statements from the commentary indexed so far, fixed at order. Final coverage is set when the report is built. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":1950,"size":"deep","size_rule":"Deep: 301+ verified HCP statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":null,"arms":[{"description":"Participants will receive 6.0 mg/kg of DS-1062a","label":"DS-1062a 6.0 mg/kg","type":"EXPERIMENTAL"}],"collaborators":["AstraZeneca"],"completion_date":{"date":"2026-02-04","type":"ACTUAL"},"conditions":["Non-small Cell Lung Cancer"],"enrollment":{"count":137,"type":"ACTUAL"},"has_results":true,"interventions":[{"name":"DS-1062a","otherNames":["Datopotamab Deruxtecan"],"type":"DRUG"}],"last_update":"2026-03-24","lead_sponsor":"Daiichi Sankyo","official_title":"Phase 2, Single-arm, Open-label Study of DS-1062a in Advanced or Metastatic Non-small Cell Lung Cancer With Actionable Genomic Alterations and Progressed On or After Applicable Targeted Therapy and Platinum Based Chemotherapy (TROPION-Lung05)","overall_status":"COMPLETED","phases":["PHASE2"],"primary_completion_date":{"date":"2023-03-10","type":"ACTUAL"},"primary_outcomes":[{"measure":"Percentage of Participants With Objective Response Rate (ORR) Based on Blinded Independent Central Review (BICR)","timeFrame":"From baseline until disease progression, death, or other protocol defined reason, up to approximately 24 months."}],"references":[{"citation":"Ahn MJ, Lisberg A, Goto Y, Sands J, Hong MH, Paz-Ares L, Pons-Tostivint E, Perol M, Felip E, Sugawara S, Hayashi H, Cho BC, Blumenschein G Jr, Shum E, Lee JS, Heist RS, Cornelissen R, Chang WC, Kowalski D, Zebger-Gong H, Chargualaf M, Gu W, Lan L, Howarth P, Joseph R, Okamoto I. A Pooled Analysis of Datopotamab Deruxtecan in Patients With EGFR-Mutated NSCLC. J Thorac Oncol. 2025 Nov;20(11):1669-1682. doi: 10.1016/j.jtho.2025.06.002. Epub 2025 Jun 12.","pmid":"40516821","type":"DERIVED"},{"citation":"Sands J, Ahn MJ, Lisberg A, Cho BC, Blumenschein G Jr, Shum E, Pons Tostivint E, Goto Y, Yoh K, Heist R, Shimizu J, Lee JS, Baas P, Planchard D, Perol M, Felip E, Su WC, Zebger-Gong H, Lan L, Liu C, Howarth P, Chiaverelli R, Paz-Ares L. Datopotamab Deruxtecan in Advanced or Metastatic Non-Small Cell Lung Cancer With Actionable Genomic Alterations: Results From the Phase II TROPION-Lung05 Study. J Clin Oncol. 2025 Apr;43(10):1254-1265. doi: 10.1200/JCO-24-01349. Epub 2025 Jan 6.","pmid":"39761483","type":"DERIVED"}],"start_date":{"date":"2021-03-30","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"Study of DS-1062a in Advanced or Metastatic Non-small Cell Lung Cancer With Actionable Genomic Alterations (TROPION-Lung05)","url":"https://clinicaltrials.gov/study/NCT04484142"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.0","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/tropion-lung05-nct04484142"}